RecruitingRecruiting
Pan-tumor MRD Study
NCT06605404 · Paradigm Health
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
About this study
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Eligibility criteria
Eligibility Criteria:
1. Age 18 years or older.
2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).
3. Eligible for curative intent therapy, with surgical resection of cancer planned.
a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
5. No systemic therapy for current cancer diagnosis administered before enrollment.
6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.
7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).
8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.
9. No prior allogeneic hematopoietic stem cell transplant.
10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.
Cohort Specific Criteria
11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:
12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.
13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.
14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.
The following tumor types are excluded:
1. Central nervous system (CNS) malignancies
2. Colorectal cancer
3. Breast cancer
4. Squamous cell skin cancer
5. Basal cell carcinoma
6. Gastrointestinal stromal tumors (GIST)
7. Thyroid cancer
8. Uveal melanoma
9. Low or intermediate grade neuroendocrine tumors
■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible
10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia
Study design
Enrollment target: 1350 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-01-08
Estimated completion: 2032-04
Last updated: 2026-09-24
Interventions
Diagnostic Test: blood and tissue samplesOther: blood and tissue samples
Primary outcomes
- • Blood and tissue biospecimen registry (Observation from enrollment to 5.5 years after enrollment)
Sponsor
Paradigm Health · industry
Contacts & investigators
ContactAnosheh Afghahi, MD · contact · anosheh.afghahi@paradigmhealth.ai · 888-662-6367
All locations (47)
Alabama OncologyRecruiting
Birmingham, Alabama, United States
Mohtaseb Cancer Center and Blood DisordersRecruiting
Bullhead City, Arizona, United States
Cancer & Blood Specialists of ArizonaRecruiting
Casa Grande, Arizona, United States
CARTIRecruiting
Little Rock, Arkansas, United States
Highlands Oncology Group (HOG)Recruiting
Springdale, Arkansas, United States
Los Angeles Cancer Network (LACN)Recruiting
Glendale, California, United States
Ventura County Hematology Oncology SpecialistsRecruiting
Oxnard, California, United States
Medical Oncology Associates of San Diego (MOASD)Recruiting
San Diego, California, United States
Medical Oncology Associates of San DiegoRecruiting
San Diego, California, United States
Stockton Hematology Oncology Med GroupRecruiting
Stockton, California, United States
The Melanoma and Skin Cancer InstituteRecruiting
Englewood, Colorado, United States
Oncology & Hematology Associates of West BrowardRecruiting
Coral Springs, Florida, United States
Mid Florida Cancer CentersRecruiting
Orange City, Florida, United States
Comprehensive Hematology Oncology (CHO)Recruiting
St. Petersburg, Florida, United States
Piedmont Cancer InstituteRecruiting
Atlanta, Georgia, United States
Cancer Care Specialists of Illinois (CCSI)Recruiting
O'Fallon, Illinois, United States
Carle HealthRecruiting
Urbana, Illinois, United States
Cotton O'Neil Cancer Center [Stormont Vail]Recruiting
Topeka, Kansas, United States
Cancer Center of KansasRecruiting
Wichita, Kansas, United States
Baptist Health CorbinRecruiting
Corbin, Kentucky, United States
Baptist Health HardinRecruiting
Elizabethtown, Kentucky, United States
Baptist Health LexingtonRecruiting
Lexington, Kentucky, United States
Baptist Health LouisvilleRecruiting
Louisville, Kentucky, United States
Pontchartrain Cancer CenterRecruiting
Covington, Louisiana, United States
Christus Health HighlandsRecruiting
Shreveport, Louisiana, United States
The Cancer & Hematology Centers (CHC)Recruiting
Grand Rapids, Michigan, United States
Mayo ClinicRecruiting
Rochester, Minnesota, United States
Cox HealthRecruiting
Springfield, Missouri, United States
Cancer Partners of NebraskaRecruiting
Lincoln, Nebraska, United States
San Juan Oncology AssociatesRecruiting
Farmington, New Mexico, United States
Guthrie Lourdes Memorial Hospital (GLMH)Recruiting
Binghamton, New York, United States
New York Cancer & Blood SpecialistsRecruiting
Shirley, New York, United States
Carolina Oncology SpecialistsRecruiting
Charlotte, North Carolina, United States
Southeastern Medical Oncology Center (SMOC)Recruiting
Goldsboro, North Carolina, United States
Regional Medical Oncology CenterRecruiting
Wilson, North Carolina, United States
Gabrail Cancer CenterRecruiting
Canton, Ohio, United States
Taylor Cancer Research CenterRecruiting
Maumee, Ohio, United States
Oklahoma Cancer Specialists and Research Institute (OCSRI)Recruiting
Tulsa, Oklahoma, United States
Oregon Health & Science University (OHSU)Recruiting
Portland, Oregon, United States
Lancaster General Hospital (UPenn)Recruiting
Lancaster, Pennsylvania, United States
Guthrie FoundationRecruiting
Sayre, Pennsylvania, United States
Cancer Care Associates of York (CCAY)Recruiting
York, Pennsylvania, United States
Onocology Consultants P.A. (Oncology Consultants [OC Houston])Recruiting
Houston, Texas, United States
Community Clinical TrialsRecruiting
Kingwood, Texas, United States
Christus St. Michael'sRecruiting
Texarkana, Texas, United States
Virginia Cancer InstituteRecruiting
Richmond, Virginia, United States
Northwest Medical Specialties (NWMS)Recruiting
Tacoma, Washington, United States